Clinical trial
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
NCT00422097 · R-Pharm, Industry · Completed
Key facts
| NCT number | NCT00422097 |
|---|---|
| Title | A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer |
| Official title | A Phase I Study of Ixabepilone Administered as a Daily Oral Dose on 5 Successive Days Every 21 Days in Subjects With Advanced Cancer |
| Lead sponsor | R-Pharm, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Ixabepilone, 5 mg/d, 10 mg/d, 15 mg/d, 20 mg/d, 25 mg/d, 30 mg/d, 25 mg, with famotidine, with food |
| Enrollment | 40 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2009 |
| Completion | Apr 1, 2011 |
| First posted | Jan 15, 2007 |
| Last update posted | Mar 10, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: